Public health emergency SOLIDARITY trial of treatments for COVID-19 infection in hospitalized patients

INTERVENTION: Adults (aged =18 years) recently hospitalized, or already in the hospital, with definite COVID‐19 and, in the view of the responsible doctor, no contra‐indication to any of the study drugs will be randomly allocated between five groups: 1. Local standard of care alone OR local standard of care plus one of 2. Remdesivir (daily infusion for 10 days) 3. Chloroquine or hydroxychloroquine (two oral loading doses, then orally twice daily for 10 days) 4. Lopinavir + ritonavir (orally twice daily for 14 days) 5. Lopinavir + ritonavir ((orally twice daily for 14 days) plus interferon‐beta (daily injection for 6 days) Follow‐up is until death or discharge from hospital. Randomization is performed at one central global location through an online portal. CONDITION: COVID‐19 (SARS‐CoV‐2 infection) ; Infections and Infestations ; COVID‐19 (SARS‐CoV‐2 infection) PRIMARY OUTCOME: All‐cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study SECONDARY OUTCOME: ; Measured using patient records:; 1. Duration of hospital stay (hours); 2. Time to first receiving ventilation (or intensive care) (hours); INCLUSION CRITERIA: 1. Adults (aged =18 years) hospitalized with definite COVID‐19 2. Not already receiving any of the study drugs 3. Without known allergy or contraindications to any of them (in the view of the physician responsible for their care) 4. Without anticipated transfer within 72 h to a non‐study hospital Patients invited to join the study will be those who are admitted to a collaborating hospital; no wider recruitment efforts are expected